Essential Dosing Differences You Need to Know
Wegovy vs Mounjaro Dosing Schedules: Key Differences for UK Buyers
When comparing Wegovy vs Mounjaro dosing schedules, the most significant difference lies in their escalation pathways and mechanisms of action. Wegovy follows a structured 5-step dose escalation over 16 weeks: starting at 0.25mg for weeks 1-4, progressing to 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and finally reaching the maintenance dose of 2.4mg from week 17 onwards. This gradual approach helps minimise gastrointestinal side effects while allowing your body to adapt to the GLP-1 receptor agonist mechanism.
Mounjaro uses a different approach with tirzepatide, featuring a 4-step escalation: 2.5mg for 4 weeks, then 5mg, 7.5mg, and up to 15mg maintenance doses. The key difference is that Mounjaro targets both GIP and GLP-1 receptors simultaneously, while Wegovy specifically targets GLP-1 receptors. Both medications are prescription-only medicines that require careful clinical supervision and must be used alongside a reduced-calorie diet and increased physical activity.
UK Pricing Structure: Wegovy vs Mounjaro Dosing Costs
EverydayMeds offers transparent pricing for Wegovy vs Mounjaro dosing options, with Wegovy starter doses beginning at £79.99 for the 0.25mg pen using code FIRST40 for new customers. Our pricing reflects the escalation schedule: 0.5mg costs £94.99, 1mg at £99.99, 1.7mg at £139.99, and the maintenance 2.4mg dose at £209.99. We also offer convenient bundles like the Intro Duo (0.25mg & 0.5mg) for £169.99, designed to support your initial dosing journey without multiple orders.
The value proposition extends beyond individual pen pricing to include our comprehensive clinical service. Every purchase includes a thorough clinical assessment, prescriber review by our GPhC-registered pharmacy team (#9012878), and cold-chain delivery to maintain medication integrity. Returning customers can use code DOSE25 at checkout, and our bundle options provide supply continuity—essential when following either medication's strict dosing schedule.
Clinical Evidence: Wegovy vs Mounjaro Dosing Effectiveness
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1, compared to 2.4% with placebo. The dosing schedule was crucial to these outcomes, with the gradual escalation allowing sustained tolerability. STEP 5 showed that this weight loss was maintained at approximately 15.2% over 2 years when patients continued their prescribed dosing regimen.
Mounjaro's SURMOUNT trials showed different results due to its dual-receptor mechanism, though direct comparison isn't appropriate given different trial designs and populations. Both medications work through appetite regulation and satiety enhancement, but their dosing approaches reflect their distinct pharmacological profiles. The key message for UK patients is that both are clinically proven when used as prescribed with proper medical supervision.
How Wegovy's Dosing Schedule Supports Weight Management
Wegovy's active ingredient, semaglutide, works as a GLP-1 receptor agonist that mimics your body's natural incretin hormones. The carefully structured dosing schedule allows these mechanisms to develop gradually—starting with appetite reduction at lower doses and progressing to enhanced satiety and reduced food cravings as you reach maintenance doses. This once-weekly injection targets brain appetite centres, helping you feel satisfied with smaller portions while reducing the psychological drive to eat. The 16-week escalation period isn't just about tolerability; it allows your body's natural weight regulation systems to adapt progressively. Each dose level builds upon the previous one, creating sustainable changes in eating behaviour that support long-term weight management goals.
Streamlined Ordering Process for Wegovy vs Mounjaro Dosing
Our ordering process recognises the complexity of choosing between Wegovy vs Mounjaro dosing schedules, which is why we've designed a comprehensive 3-step pathway. First, complete our 3-minute clinical assessment that covers your weight management history, current medications, and specific dosing preferences—this helps our prescribers understand whether Wegovy's 5-step escalation or Mounjaro's 4-step approach might suit your circumstances better. Second, our qualified prescribers (operating under GPhC registration #9012878) review your assessment within 3 working days (or 24 hours with express review), providing personalised guidance on dosing schedules and expected timelines. Finally, once approved, we dispatch your medication via next-day cold-chain delivery, ensuring the integrity required for both injectable treatments. This process ensures you receive the right medication with proper clinical oversight, regardless of which dosing schedule you ultimately pursue.
Storage Advantages: Wegovy vs Mounjaro Dosing Practicalities
A significant practical difference in Wegovy vs Mounjaro dosing relates to storage flexibility, particularly important for UK patients managing work, travel, or lifestyle commitments. Wegovy pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended stability supports the longer dosing intervals and provides greater flexibility for business travel or holiday periods. Both medications should be stored in the refrigerator at 2-8°C before first use, and both use pre-filled injection pens designed for once-weekly administration. The FlexTouch pen system used for Wegovy is specifically engineered for the semaglutide formulation, while Mounjaro uses its own delivery system optimised for tirzepatide's different concentration requirements.
Making the Choice: Personalised Wegovy vs Mounjaro Dosing Decisions
The decision between Wegovy vs Mounjaro dosing schedules often comes down to individual clinical factors, lifestyle preferences, and how your body responds to different mechanisms of action. Some patients prefer Wegovy's more gradual 5-step escalation, particularly if they have a history of gastrointestinal sensitivity or want a more measured approach to weight management. Others may be suited to Mounjaro's dual-receptor targeting, though this requires discussion with a qualified prescriber who can assess your complete medical history.
At EverydayMeds, we don't advocate for one medication over another—instead, we ensure both Wegovy and Mounjaro are available with comprehensive clinical support. Your prescriber can help determine which dosing schedule aligns with your weight management goals, existing health conditions, and lifestyle factors. This personalised approach ensures you receive the most appropriate treatment with proper ongoing supervision and support throughout your chosen dosing journey.
Secure Your Wegovy vs Mounjaro Dosing Consultation Today
Ready to explore your options for Wegovy vs Mounjaro dosing schedules? Start with our clinical assessment to discuss your weight management goals with qualified UK prescribers. New customers can use code FIRST40 at checkout, while returning customers save with DOSE25—these discounts apply to our transparent pricing structure. Whether you choose Wegovy's proven semaglutide pathway or prefer to explore Mounjaro's dual-receptor approach, our clinical team provides the expertise you need for informed decision-making. Visit https://everydaymeds.co.uk/collections/wegovy to begin your assessment, or contact our patient support team for guidance on which dosing schedule might suit your circumstances. Both medications represent significant advances in prescription weight management, and our role is ensuring you access them safely, legally, and with comprehensive clinical support throughout your treatment journey.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
